Yang Ping, Peng Shu-Jia, Dong Yan-Ming, Yang Lin, Yang Zhen-Yu, Hu Xi-E, Bao Guo-Qiang
Department of General Surgery, Tangdu Hospital, Air Force Military Medical University, Xi'an 710032, Shaanxi Province, China.
World J Clin Cases. 2020 Dec 6;8(23):6036-6042. doi: 10.12998/wjcc.v8.i23.6036.
Apocrine carcinoma of the breast is a special type of invasive ductal carcinoma of the breast that is rare in clinical practice. Neoadjuvant therapy, especially neoadjuvant targeted therapy, has rarely been reported for apocrine carcinoma of the breast.
A 63-year-old woman presented with apocrine carcinoma of the left breast underwent core needle biopsy. The patient was diagnosed with apocrine carcinoma by immunohistochemical staining and negative hormone status (estrogen receptor and progesterone receptor) but showed overexpression of human epidermal factor receptor 2 (HER-2). Moreover, positive expression of androgen receptor (approximately 60%) and gross cystic disease fluid protein 15 was observed. The patient was treated with neoadjuvant targeted therapy consisting of the TCH regimen (docetaxel, carboplatin area under curve 6 and trastuzumab) every 21 d. The mass in the left breast was significantly reduced, and pain in the breast and left upper arm also improved.
HER-2 positive apocrine carcinoma of the breast can be improved by neoadjuvant chemotherapy combined with targeted therapy.
乳腺大汗腺癌是一种特殊类型的乳腺浸润性导管癌，临床实践中较为罕见。新辅助治疗，尤其是新辅助靶向治疗，在乳腺大汗腺癌中的报道很少。
一名63岁女性因左乳腺大汗腺癌接受粗针活检。患者经免疫组化染色及激素状态（雌激素受体和孕激素受体）阴性确诊为大汗腺癌，但显示人表皮生长因子受体2（HER-2）过表达。此外，观察到雄激素受体阳性表达（约60%）和巨大囊肿病液体蛋白15阳性。患者接受每21天一次的TCH方案（多西他赛、曲线下面积为6的卡铂和曲妥珠单抗）新辅助靶向治疗。左乳肿块明显缩小，乳房及左上臂疼痛也有所改善。
HER-2阳性乳腺大汗腺癌可通过新辅助化疗联合靶向治疗得到改善。
